Drug Profile
MCS 5
Latest Information Update: 14 Oct 2021
Price :
$50
*
At a glance
- Originator Health Ever Bio-Tech
- Class Male infertility therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Male infertility
Most Recent Events
- 14 Oct 2021 Discontinued - Phase-II for Male infertility in Taiwan (unspecified route) (Health Ever Bio-Tech pipeline, October 2021)
- 23 Jan 2018 MCS 5 is still in phase II trials for Male infertility in South Korea (Health Ever Biotech pipeline, January 2018)
- 28 Dec 2015 MCS 5 is still in phase II trials for Male infertility in Taiwan (NCT01016340, Health Ever Bio-Tech pipeline)